Artificial Intelligence (AI) pioneer Anthropic has declared ambitious plans to wipe out cancer within the next ten years, partnering with six biotech companies to accelerate drug discovery for various diseases. The announcement comes as a response to growing interest in AI's potential role in identifying and designing drugs more efficiently, thereby reducing costs and time in medical research.
One of Anthropic's collaborations involves Generate Biomedicines, aiming to adapt CAR T-cell therapy - traditionally used against blood cancers - for solid tumors. Using the AI chatbot Claude Code, scientists from Generate have proposed a redesigned version of a section of the therapy's genetic instructions that could potentially kill cancer cells more effectively and for longer periods. Laboratory tests showed promising results, with immune cells producing significantly more receptors and improved ability to destroy tumor cells.
Another collaboration with BigHat Biosciences focuses on enhancing two potential drug candidates, including one designed to target cancer cells. Through rigorous testing of over 1,000 variations, researchers discovered a superior version that binds to its target more than ten times as tightly as the original.
In addition to these partnerships, Anthropic's collaboration with Divergence Labs produced around 35,000 antibody designs in approximately a month for a potential food allergy treatment. Separately, work with Enveda reduced human review time for manufacturing documents by 89 percent.
Anthropic has also embarked on its own drug discovery programs, including research into rare childhood forms of muscular dystrophy. One of their potential muscular dystrophy drug candidates could enter human clinical trials as early as late 2028, subject to the continued promising results. However, much of this research remains at the preclinical stage, meaning the potential treatments have not yet undergone human testing.